Cargando…
From the Clinic to the Laboratory, and Back Again: Investigations on Cannabinoids and Endocannabinoid System Modulators for Treating Schizophrenia
The present mini-review focuses on animal models of schizophrenia that have explored the effects of cannabidiol (CBD; a non-psychoactive component of cannabis) or the pharmacological manipulation of the endocannabinoid system on behavioral and cognitive outcome measures. First, results of some relev...
Autor principal: | Hoffman, Kurt Leroy |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8287066/ https://www.ncbi.nlm.nih.gov/pubmed/34290632 http://dx.doi.org/10.3389/fpsyt.2021.682611 |
Ejemplares similares
-
Role of cannabinoids and the endocannabinoid system in modulation of diabetic cardiomyopathy
por: El-Azab, Mona F, et al.
Publicado: (2022) -
The Endocannabinoid System, Cannabinoids, and Pain
por: Fine, Perry G., et al.
Publicado: (2013) -
Modulation of the Endocannabinoid System: Vulnerability Factor and New Treatment Target for Stimulant Addiction
por: Olière, Stéphanie, et al.
Publicado: (2013) -
Cannabinoids, Endocannabinoids and Sleep
por: Kesner, Andrew J., et al.
Publicado: (2020) -
Plasma Endocannabinoid Alterations in Individuals with Substance Use Disorder are Dependent on the “Mirror Effect” of Schizophrenia
por: Desfossés, Joëlle, et al.
Publicado: (2012)